| 李鹏远,王晓芳,刘 月,张慧英,张清华,张丽娇.康力欣胶囊联合FOLFOX4方案对中晚期胃癌患者免疫功能、生活质量和血清肿瘤标志物的影响[J].现代生物医学进展英文版,2022,(1):73-77. |
| 康力欣胶囊联合FOLFOX4方案对中晚期胃癌患者免疫功能、生活质量和血清肿瘤标志物的影响 |
| Effect of Kanglixin Capsule Combined with FOLFOX4 Regimen on Immune Function, Quality of Life and Serum Tumor Markers in Patients with Advanced Gastric Cancer |
| Received:May 26, 2021 Revised:June 22, 2021 |
| DOI：10.13241/j.cnki.pmb.2022.01.012 |
| 中文关键词: 康力欣胶囊 FOLFOX4方案 中晚期 胃癌 免疫功能 生活质量 肿瘤标志物 |
| 英文关键词: Kanglixin capsule FOLFOX4 regimen Advanced Gastric cancer Immune function Quality of life Tumor markers |
| 基金项目:北京市自然科学基金项目（7204272） |
|
| Hits: 1067 |
| Download times: 568 |
| 中文摘要: |
| 摘要 目的：观察康力欣胶囊联合奥沙利铂、亚叶酸钙、5-氟尿嘧啶（FOLFOX4）方案对中晚期胃癌患者免疫功能、生活质量和血清肿瘤标志物的影响。方法：前瞻性选取2018年7月~2021年1月期间来我院接受治疗的胃癌患者80例，根据抽签分为对照组和观察组两组，各为40例。对照组接受FOLFOX4方案治疗，观察组接受康力欣胶囊联合FOLFOX4方案治疗，以3周为1个疗程，治疗2个疗程。观察两组治疗2个疗程后的疗效、生活质量以及治疗期间不良反应状况，对比两组治疗前、治疗2个疗程后的肿瘤标志物和免疫功能指标变化情况。结果：观察组治疗2个疗程后的总有效率高于对照组（P<0.05）。治疗2个疗程后，观察组的肿瘤相关物质群（TSGF）、糖类抗原-199（CA-199）、癌胚抗原（CEA）低于对照组（P<0.05）。治疗2个疗程后，观察组的CD3+、CD4+、自然杀伤细胞（NK）、CD4+/ CD8+高于对照组，CD8+低于对照组（P<0.05）。治疗2个疗程后，观察组的生活质量总改善率、卡氏评分（KPS）评分高于对照组（P<0.05）。两组不良反应发生率组间对比无统计学差异（P>0.05）。结论：中晚期胃癌患者采用康力欣胶囊联合FOLFOX4方案治疗，在阻止疾病进展、改善生活质量、提高免疫功能方面均效果确切，优于单纯化疗效果。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of Kanglixin capsule combined with oxaliplatin, calcium folinate and 5-fluorouracil (FOLFOX4) on immune function, quality of life and serum tumor markers in patients with advanced gastric cancer. Methods: 80 patients with gastric cancer in our hospital from July 2018 to January 2021 were prospectively selected. They were divided into two groups: control group and observation group according to the drawing, 40 cases in each group. The control group received FOLFOX4 regimen treatment, and the observation group received Kanglixin capsule combined with FOLFOX4 regimen treatment, 3 weeks as a course of treatment, 2 courses of treatment. The efficacy, quality of life at 2 courses after treatment and adverse reactions during treatment of the two groups were observed, the changes of tumor markers and immune function indexes before treatment and 2 courses after treatment were compared between the two groups. Results: The total effective rate of the observation group at 2 courses after treatment was higher than that of the control group (P<0.05). 2 courses after treatment, tumor supplied group of factors (TSGF), carbohydrate antigen-199 (CA-199), carcinoembryonic antigen (CEA) of the observation group were lower than those of the control group (P<0.05). 2 courses after treatment, CD3+, CD4+, natural killer cells (NK), CD4+/ CD8+ of the observation group were higher than those of the control group, and CD8+ was lower than that of the control group (P<0.05). 2 courses after treatment, the total improvement rate of quality of life and Karnofsky scale (KPS) score of the observation group were higher than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Kanglixin capsule combined with FOLFOX4 regimen for patients with advanced gastric cancer has proven effective in preventing disease progression, improving life quality and improving immune function, which is better than chemotherapy alone. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
